pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
Nektar Therapeutics UK clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
Nektar Therapeutics UK projects
11 ClinicalTrials.gov programs sponsored by Nektar Therapeutics UK.
Nektar Therapeutics UK has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Amikacin Inhalation Solution (BAY41-6551)
Nektar Therapeutics UK Limited
Pneumonia, Bacterial
1 trial -
Bempegaldesleukin
Nektar Therapeutics UK Limited
Metastatic Head and Neck Cancer
1 trial -
Bempegaldesleukin
Nektar Therapeutics UK Limited
Melanoma
1 trial -
Inhaled Human Insulin
Nektar Therapeutics UK Limited
Diabetes Mellitus, Type 2
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Locally Recurrent Breast Cancer
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Metastasis
1 trial -
NKTR-181 BID tablets
Nektar Therapeutics UK Limited
Low Back Pain
2 trials -
NKTR-214
Nektar Therapeutics UK Limited
Melanoma
1 trial -
NKTR-255 at 1.5 µg/kg
Nektar Therapeutics UK Limited
Non-Hodgkin Lymphoma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Bladder Cancer
1 trial -
bempegaldesleukin
Nektar Therapeutics UK Limited
Renal Cell Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Nektar Therapeutics UK have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.